Malignant Peripheral Nerve Sheath Tumor (MPNST), from the CureRays guide library.

A malignant peripheral nerve sheath tumor is an aggressive soft-tissue cancer that grows from the protective lining of a nerve, often arising in people with the inherited condition neurofibromatosis type 1; treatment centers on complete surgery, with radiation used to control the microscopic disease that spreads along the nerve and to lower the chance of it coming back.

What it is.

A malignant peripheral nerve sheath tumor (MPNST) is a soft-tissue sarcoma that begins in the cells that wrap and insulate the body's peripheral nerves — the nerves that run from the spinal cord out to the limbs and trunk. It is an aggressive cancer that grows quickly, invades nearby tissue, and can spread to distant organs, most often the lungs. MPNST arises in two main settings. About half of cases occur in people with neurofibromatosis type 1 (NF1), an inherited condition in which benign nerve tumors called neurofibromas are common; occasionally one of these benign tumors — particularly a large, deep 'plexiform' neurofibroma — transforms into a cancer. The other half occur sporadically, with no underlying NF1, and a small number develop years after radiation was given to that area for a different cancer. Because MPNST grows along the path of a nerve, it can cause a growing mass together with nerve symptoms such as pain, numbness, tingling, or weakness in the area the nerve supplies. In a person with NF1, a neurofibroma that suddenly starts growing, becomes painful, or causes new neurological symptoms is an important warning sign that should be evaluated promptly. The cornerstone of treatment is surgery to remove the tumor completely with a margin of healthy tissue; because the cancer extends microscopically along the nerve beyond the visible mass, radiation is frequently combined with surgery to treat that wider zone and reduce the chance of the cancer returning, while chemotherapy plays a more limited and selective role.

How radiation treats it.

Radiation therapy treats MPNST by delivering precisely aimed beams of energy that damage the DNA inside tumor cells so they can no longer grow and divide. It is a frequent partner to surgery because of the distinctive way this cancer grows. Soft-tissue sarcomas in general push microscopic fingers of tumor into the surrounding tissue beyond the visible mass, but MPNST adds a further challenge: it tracks along the length of the nerve from which it arose, so cancer cells can extend well beyond what is seen on a scan. If only the obvious tumor were removed, those extensions could be left behind and seed a recurrence. Radiation treats a wider zone — including the path of the nerve — sterilizing that microscopic disease so the operation can be smaller and more likely to preserve function, and so the cancer is far less likely to return locally. Radiation can be given before or after surgery. Before surgery it uses a smaller treatment area and a lower dose and can make a complete removal more achievable; after surgery it treats the tumor bed and the nerve's course at a higher dose when needed. Because these tumors are often deep and irregular and may sit near the spinal cord, eyes, or other sensitive structures, modern techniques are important: intensity-modulated radiation shapes the dose tightly around the target while sparing nearby tissue, and proton therapy can further reduce dose to critical structures, which is particularly valuable for tumors near the spine, in younger patients, or when an area has been irradiated before — a relevant concern since some MPNSTs themselves arise in previously radiated tissue. Radiation also has a role beyond the original site: when MPNST spreads to a limited number of spots in the lungs, focused high-dose stereotactic body radiation can ablate those deposits without surgery.

The ways we can treat it.

Preoperative (neoadjuvant) radiation. Radiation before surgery treats the microscopic disease extending along the nerve using a smaller field and lower dose, and can make a complete, function-preserving removal more achievable.

Postoperative (adjuvant) radiation. Radiation to the tumor bed and the nerve's path after surgery sterilizes microscopic disease left behind, lowering the chance of local recurrence, at a higher dose over a larger area.

Intensity-modulated radiation (IMRT). Shaping the beams tightly around the target and the nerve's course spares surrounding muscle, bowel, spinal cord, and other tissues, which is important for these often deep, irregular tumors.

Proton therapy (selected cases). Proton beams deposit their energy at a precise depth and stop, reducing dose to nearby critical structures — useful for tumors near the spine or in young patients, and when re-treatment of a previously irradiated area is needed.

Stereotactic body radiation (SBRT) for metastases. Focused, high-dose radiation can ablate a limited number of lung deposits without surgery, providing durable control of isolated metastases.

Questions we hear often.

I have neurofibromatosis type 1 — does that mean I will get MPNST? No. Most people with NF1 never develop MPNST. But NF1 does raise the lifetime risk, and most NF1-related MPNSTs arise from a pre-existing deep (plexiform) neurofibroma that begins to change. That is why it helps to know the warning signs: a neurofibroma that suddenly starts growing, becomes persistently painful, feels hard, or causes new numbness, tingling, or weakness should be evaluated promptly. Imaging, sometimes including a PET scan, and a biopsy can determine whether a tumor has transformed. Catching that change early makes complete removal — and cure — more likely.

Why is radiation used if the surgeon removes the whole tumor? Because MPNST doesn't stay neatly within the visible mass. Like other sarcomas it sends microscopic fingers of tumor into the surrounding tissue, and it also grows along the length of the nerve it came from, so cancer cells can extend well beyond what shows up on a scan. Radiation treats that wider zone, including the nerve's path, sterilizing the microscopic disease so the cancer is much less likely to return at the original site. It also allows surgeons to perform a smaller, more function-preserving operation. For most high-grade MPNSTs, combining radiation with surgery gives better local control than surgery alone.

Does chemotherapy help with MPNST? Its role is more limited than in some other sarcomas. Chemotherapy is considered mainly for large, high-grade tumors at higher risk of spreading, and for disease that has already spread, but the evidence that it improves long-term outcomes is less certain for MPNST. As a result, treatment focuses on complete surgery and radiation for disease confined to one area. Because better systemic options are needed, clinical trials of targeted drugs aimed at the specific molecular changes in MPNST are an important option to discuss, especially for advanced disease.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.